Literature DB >> 23440289

High mobility group box 1 and kidney diseases (Review).

Ping Zhu1, Li Xie, Hua-Sheng Ding, Quan Gong, Jian Yang, Lin Yang.   

Abstract

High mobility group box 1 (HMGB1), a non-histone DNA-binding protein, regulates nucleosome function and transcription in the nuclei of all metazoans and plants. However, extracellular HMGB1, which is actively or passively released under different conditions, can act as a key inflammatory mediator through MyD88/mitogen-activated protein kinase signaling by binding to its receptors including the receptor for advanced glycation end products or Toll-like receptors. A growing body of evidence indicates that HMGB1 plays an important role in kidney diseases, such as glomerulonephritis, lupus nephritis, antineutrophilic cytoplasmatic antibody-associated vaculitis, diabetic nephropathy, renal allograft rejection and acute kidney injury. In this review, we focus on the biology of HMGB1 and the association of HMGB1 with kidney diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23440289     DOI: 10.3892/ijmm.2013.1286

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  11 in total

1.  HMGB1, TGF-β and NF-κB are associated with chronic allograft nephropathy.

Authors:  Shi-Qi Zhao; Zhen-Zhen Xue; Ling-Zhang Wang
Journal:  Exp Ther Med       Date:  2017-10-17       Impact factor: 2.447

2.  Histologic and Molecular Patterns in Responders and Non-responders With Chronic-Active Antibody-Mediated Rejection in Kidney Transplants.

Authors:  Onur Sazpinar; Ariana Gaspert; Daniel Sidler; Markus Rechsteiner; Thomas F Mueller
Journal:  Front Med (Lausanne)       Date:  2022-04-29

Review 3.  HMGB1 in health and disease.

Authors:  Rui Kang; Ruochan Chen; Qiuhong Zhang; Wen Hou; Sha Wu; Lizhi Cao; Jin Huang; Yan Yu; Xue-Gong Fan; Zhengwen Yan; Xiaofang Sun; Haichao Wang; Qingde Wang; Allan Tsung; Timothy R Billiar; Herbert J Zeh; Michael T Lotze; Daolin Tang
Journal:  Mol Aspects Med       Date:  2014-07-08

4.  High Mobility Group Box 1 Promotes Aortic Calcification in Chronic Kidney Disease via the Wnt/β-Catenin Pathway.

Authors:  Xiucai Jin; Shu Rong; Weijie Yuan; Lijie Gu; Jieshuang Jia; Ling Wang; Honglei Yu; Yifeng Zhuge
Journal:  Front Physiol       Date:  2018-06-05       Impact factor: 4.566

5.  Complement-mediated Damage to the Glycocalyx Plays a Role in Renal Ischemia-reperfusion Injury in Mice.

Authors:  Anjan K Bongoni; Bo Lu; Jennifer L McRae; Evelyn J Salvaris; Erik J M Toonen; Ingela Vikstrom; Adriana Baz Morelli; Martin J Pearse; Peter J Cowan
Journal:  Transplant Direct       Date:  2019-03-25

6.  High-mobility group box 1 protein antagonizes the immunosuppressive capacity and therapeutic effect of mesenchymal stem cells in acute kidney injury.

Authors:  Shuo Wang; Songjie Cai; Weitao Zhang; Xigao Liu; Yan Li; Chao Zhang; Yigang Zeng; Ming Xu; Ruiming Rong; Tianshu Yang; Benkang Shi; Anil Chandraker; Cheng Yang; Tongyu Zhu
Journal:  J Transl Med       Date:  2020-04-20       Impact factor: 5.531

7.  Serum level of high mobility group box protein-1 and prognosis of patients with end-stage renal disease on hemodialysis and peritoneal dialysis.

Authors:  Linyan Chen; Gaoping Chen; Xiangdong Kong
Journal:  Medicine (Baltimore)       Date:  2021-02-05       Impact factor: 1.817

Review 8.  Receptor for Advanced Glycation Endproducts (RAGE), Its Ligands, and Soluble RAGE: Potential Biomarkers for Diagnosis and Therapeutic Targets for Human Renal Diseases.

Authors:  Eun Ji Lee; Jong Hoon Park
Journal:  Genomics Inform       Date:  2013-12-31

Review 9.  Redox Signaling in Diabetic Nephropathy: Hypertrophy versus Death Choices in Mesangial Cells and Podocytes.

Authors:  Gina Manda; Alexandru-Ionel Checherita; Maria Victoria Comanescu; Mihail Eugen Hinescu
Journal:  Mediators Inflamm       Date:  2015-09-27       Impact factor: 4.711

10.  Soluble Receptor for Advanced Glycation End Product Ameliorates Chronic Intermittent Hypoxia Induced Renal Injury, Inflammation, and Apoptosis via P38/JNK Signaling Pathways.

Authors:  Xu Wu; Wenyu Gu; Huan Lu; Chengying Liu; Biyun Yu; Hui Xu; Yaodong Tang; Shanqun Li; Jian Zhou; Chuan Shao
Journal:  Oxid Med Cell Longev       Date:  2016-09-05       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.